Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
Healthcare
$0.69 -3.42%
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
52W Low $0.89High $2.09
Volume 0.17M
Average 0.13M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$3.69M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$9.71M
FY 2025 · Annual
+53.2% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Depreciation & Amortization | 0 | 0 | 0 | 4.34M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 6.87M | 5.29M |
| Change in Working Capital | 18.74K | 385.49K | 113.84K | 126.47K | 594.69K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 18.74K | 0 | 114.56K | 183.63K | (50.77K) |
| Other Working Capital | 18.74K | 385.49K | (713) | (57.16K) | 645.46K |
| Other Non-Cash Items | 0 | 385.49K | 9.1M | 130K | 840K |
| Operating Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
| Capital Expenditures | (4) | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 462.39K | 3.17M | (101K) | 0 |
| Common Stock Issued | 0 | 0 | 1M | 6.83M | 9.55M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 119.4K | 7.69K | (310.38K) | (396.65K) | 155.52K |
| Financing Cash Flow | 119.4K | 470.08K | 3.86M | 6.34M | 9.71M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 1.42K | (188) | 1.26M | 6.02M |
| Free Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$10.4M
+ D&A$0
+ Stock-Based Comp$5.3M
+ Deferred Tax$0
+ Working Capital$594.7K
+ Other Non-Cash$840.0K
= Operating Cash Flow-$3.7M
- Capex$0
= Free Cash Flow-$3.7M
Analysis
FY2025 free cash flow is -$3.7M. FCF conversion is 35.4% of net income. Operating cash flow was -$3.7M, with capex of $0. The largest bridge item is Stock-Based Comp at $5.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3 | S-3 filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 6, 2026 | |
| 8-K | Current report | Sep 17, 2026 | |
| 8-K | Current report | Sep 16, 2026 | |
| 8-K | Current report | Sep 14, 2026 |
Does TELO generate free cash flow?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) generated -$3.69M of free cash flow in fiscal 2025.
How much operating cash flow does TELO produce?
Operating cash flow was -$3.69M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.